Holen Sie sich die Stockscreener-App
22.28
8.05%
1.66
Handel nachbörslich:
22.28
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.3%What's Next? - MarketBeat
Lifesci Capital Has Positive Outlook of SYRE FY2024 Earnings - Defense World
FY2024 EPS Forecast for Spyre Therapeutics Lifted by Analyst - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Given "Outperform" Rating at Wedbush - MarketBeat
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts - PR Newswire
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 9.2%Here's Why - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Jane Street Group LLC - Defense World
Spyre Therapeutics Awards Key Employee Stock Options at $24.35 with 10-Year Term - StockTitan
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $51.50 - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Geode Capital Management LLC Has $26.21 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Geode Capital Management LLC Purchases 125,214 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Contrasting Spyre Therapeutics (NASDAQ:SYRE) & Generation Bio (NASDAQ:GBIO) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 2.5%Here's Why - MarketBeat
Barclays PLC Buys 41,424 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Barclays PLC Boosts Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics is Now Oversold (SYRE) - Nasdaq
State Street Corp Buys 131,896 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 3,680 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Added to the Nasdaq Biotechnology Index - PR Newswire
Evercore ISI Group Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - MSN
Jones Trading Initiates Coverage of Spyre Therapeutics (SYRE) with Hold Recommendation - MSN
The Manufacturers Life Insurance Company Has $1.28 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics: Different Name, Same Tune (NASDAQ:SYRE) - Seeking Alpha
Wellington Management Group LLP Has $44.33 Million Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Charles Schwab Investment Management Inc. Has $9.80 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Janus Henderson Group PLC - MarketBeat
61,256 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Cinctive Capital Management LP - MarketBeat
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $48.57 - MarketBeat
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodies - Yahoo Finance
Spyre begins Phase 1 trials for new IBD treatments By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Fmr LLC - MarketBeat
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies - PR Newswire
Spyre Therapeutics Launches Phase 1 Trials for Revolutionary Long-Acting IBD Treatment - StockTitan
Walleye Capital LLC Increases Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Braidwell LP - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation - AccessWire
SYRESpyre Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect - AccessWire
Spyre Therapeutics’ $200 Million Common Stock Offering - Global Legal Chronicle
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - PR Newswire
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):